New drug duo aims to fight fatty liver and diabetes together
NCT ID NCT07570810
First seen May 14, 2026 · Last updated May 15, 2026 · Updated 1 time
Summary
This study is testing whether a new drug called CS0159, when combined with the diabetes drug semaglutide, can help people with fatty liver disease, obesity, and type 2 diabetes. About 30 adults will take the combination or a placebo for 12 weeks. The main goals are to see if it helps with weight loss and changes how the body uses energy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.